Science Evolution At FDA ‘Transformative,’ Advisors Say
This article was originally published in The Gray Sheet
Executive Summary
An FDA Science Board subcommittee report finds industry and researcher perceptions of FDA's science readiness has improved over the past eight years. But the agency still faces major challenges tied to the current speed of scientific and technical progress.
You may also be interested in...
In Case You Missed It: Top 10 "Gray Sheet" Stories In September
Our most popular stories last month focused on tips from FDA experts on facility inspections, various legal trends, and Robert Califf's nomination to head FDA, among other topics.
FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?
21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.